

Resource Summary Report

Generated by [NIF](#) on Aug 17, 2026

B6;129P3-Slc14a2^{tm1}

RRID:IMSR_CARD:572

Type: Organism

Proper Citation

RRID:IMSR_CARD:572

Organism Information

URL: <https://cardmice.com/rbase/strain?strainid=572>

Proper Citation: RRID:IMSR_CARD:572

Description: Mus musculus with name B6;129P3-Slc14a2^{tm1} from IMSR.

Species: Mus musculus

Notes: gene symbol note: solute carrier family 14 (urea transporter); member 2; mutant stock: Slc14a2 (human synonym: UT2)

Affected Gene: solute carrier family 14 (urea transporter); member 2

Genomic Alteration: targeted mutation 1

Catalog Number: CARD:572

Database: Center for Animal Resources and Development

Database Abbreviation: CARD

Availability: embryo

Organism Name: B6;129P3-Slc14a2^{tm1}

Record Creation Time: 20250513T061413+0000

Record Last Update: 20260815T054720+0000

Ratings and Alerts

No rating or validation information has been found for B6;129P3-Slc14a2^{tm1}.

No alerts have been found for B6;129P3-Slc14a2^{tm1}.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Center for Animal Resources and Development

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Qin M, et al. (2026) SLC13A2-transported citrate remodels transcriptional regulation through protein acetylation to suppress tumor growth. *Science advances*, 12(15), eaec4368.

Pastrana CC, et al. (2026) Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage. *Cancer research*, 86(14), 3537.

Fenoglio S, et al. (2026) Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens. *Cell reports methods*, 6(7), 101470.

Zhong M, et al. (2025) Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma. *Clinical epigenetics*, 17(1), 74.

Cheng J, et al. (2025) Targeting intracellular LMP2 with costimulatory signal-armed antibody-like TCR T cells. *JCI insight*, 10(10).

Cheng Y, et al. (2025) Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. *Molecular therapy : the journal of the American Society of Gene Therapy*, 33(4), 1535.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Conn BP, et al. (2025) Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. *Cell reports methods*, 5(5), 101049.

Chatterjee D, et al. (2025) KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance. *Molecular cancer research : MCR*, 23(6), 553.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. *iScience*, 28(6), 112584.

Gaspar M, et al. (2025) An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. *Journal for immunotherapy of cancer*, 13(8).

Duan H, et al. (2024) Chiglitazar diminishes the warburg effect through PPAR γ /mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia.

Experimental hematology & oncology, 13(1), 121.

Skidmore LK, et al. (2024) Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer. *Molecular cancer therapeutics*, 23(12), 1842.

Baldwin JG, et al. (2024) Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy. *Cell*.

Lazure F, et al. (2023) Transcriptional reprogramming of skeletal muscle stem cells by the niche environment. *Nature communications*, 14(1), 535.

Deng M, et al. (2023) The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression. *Scientific reports*, 13(1), 18554.

Gutierrez-Barbosa H, et al. (2023) A Comparison of Lymphoid and Myeloid Cells Derived from Human Hematopoietic Stem Cells Xenografted into NOD-Derived Mouse Strains. *Microorganisms*, 11(6).

Antal CE, et al. (2023) A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. *Nature communications*, 14(1), 5195.

Demeule M, et al. (2022) The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells. *Pharmaceutics*, 14(9).

Kemper K, et al. (2022) Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models. *Life science alliance*, 5(11).